随机临床试验:在质子泵抑制剂治疗基础上加用海藻酸盐-抗酸剂(Gaviscon Double Action)治疗突破性症状患者
两项随机双盲研究评估在每日一次标准剂量PPI基础上加用Gaviscon对突破性反流症状的疗效:探索性研究(n=52)中Gaviscon组HRDQ评分降低显著优于安慰剂,确认性研究(n=262)中Gaviscon组应答率51% vs 安慰剂组48%,无显著差异。
要点
- 探索性研究:Gaviscon组HRDQ评分降低优于安慰剂,最小二乘均值差-2.10(95%CI -3.71至-0.48),P=.012。
- 探索性研究事后应答分析:Gaviscon组75%达到应答 vs 安慰剂组36%,P=.005。
- 确认性研究:Gaviscon组应答率51% vs 安慰剂组48%,OR 1.15(95%CI 0.69-1.91),P=.5939,无显著差异。
核心结论
- 在PPI治疗基础上加用Gaviscon可减轻突破性GERD症状,但安慰剂组也观察到几乎相同的应答。
- 干预应答可能因症状是否为功能性起源而不同。
研究设计与样本
- 两项随机双盲研究:探索性研究n=52,确认性研究n=262。
- 患者为服用标准剂量PPI仍有突破性症状者,以HRDQ评估,随机加用Gaviscon或安慰剂(餐后及睡前20 mL)。
- 探索性研究终点为治疗期与导入期相比HRDQ评分变化;确认性研究终点为「应答」,定义为治疗期与导入期相比「不良」天数(HRDQ[烧心/反流]>0.70)减少≥3天。
主要发现
- 探索性研究:Gaviscon组HRDQ评分(烧心/反流)降低显著大于安慰剂组,最小二乘均值差-2.10(95%CI -3.71至-0.48),P=.012。
- 探索性研究事后「应答者」分析:Gaviscon组75%达到「不良」天数减少≥3天 vs 安慰剂组36%,P=.005。
- 确认性研究:加用Gaviscon组症状改善51%,但与安慰剂组48%相比无显著差异,OR 1.15(95%CI 0.69-1.91),P=.5939。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Symptomatic breakthrough in proton pump inhibitor (PPI)-treated gastro-oesophageal reflux disease (GERD) patients is a common problem with a range of underlying causes. The nonsystemic, raft-forming action of alginates may help resolve symptoms. AIM: To assess alginate-antacid (Gaviscon Double Action, RB, Slough, UK) as add-on therapy to once-daily PPI for suppression of breakthrough reflux symptoms. METHODS: In two randomised, double-blind studies (exploratory, n=52; confirmatory, n=262), patients taking standard-dose PPI who had breakthrough symptoms, assessed by Heartburn Reflux Dyspepsia Questionnaire (HRDQ), were randomised to add-on Gaviscon or placebo (20 mL after meals and bedtime). The exploratory study endpoint was change in HRDQ score during treatment vs run-in. The confirmatory study endpoint was "response" defined as ≥3 days reduction in the number of "bad" days (HRDQ [heartburn/regurgitation] >0.70) during treatment vs run-in. RESULTS: In the exploratory study, significantly greater reductions in HRDQ scores (heartburn/regurgitation) were observed in the Gaviscon vs placebo (least squares mean difference [95% CI] -2.10 [-3.71 to -0.48]; P=.012). Post hoc "responder" analysis of the exploratory study also revealed significantly more Gaviscon patients (75%) achieved ≥3 days reduction in "bad" days vs placebo patients (36%), P=.005. In the confirmatory study, symptomatic improvement was observed with add-on Gaviscon (51%) but there was no significant difference in response vs placebo (48%) (OR (95% CI) 1.15 (0.69-1.91), P=.5939). CONCLUSIONS: Adding Gaviscon to PPI reduced breakthrough GERD symptoms but a nearly equal response was observed for placebo. Response to intervention may vary according to whether symptoms are functional in origin.
引用
- Coyle C, Crawford G, Wilkinson J, et al. Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms. Aliment Pharmacol Ther. 2017. PMID: 28464343. doi:10.1111/apt.14064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。